Johnson & Johnson announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational study of icotrokinra, or JNJ-2113, the first targeted oral peptide that selectively blocks the ...
Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ETCompany ParticipantsMichael Bodner - Group President, ...
GlobalData on MSN3d
Johnson & Johnson MedTech announces partnership for soft tissue solutions"Johnson & Johnson MedTech announces partnership for soft tissue solutions" was originally created and published by Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback